NPCE vs LUNG

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 05, 2026

NPCE

50.1
AI Score
VS
NPCE Wins

LUNG

33.8
AI Score

Investment Advisor Scores

NPCE

50score
Recommendation
HOLD

LUNG

34score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric NPCE LUNG Winner
Revenue 66.18M 44.83M LUNG
Net Income -32.13M -12.89M NPCE
Gross Margin 77.3% 82.4% NPCE
Net Margin -48.5% -28.8% NPCE
Operating Income -29.50M -10.75M NPCE
ROE -93.9% -108.5% LUNG
ROA -29.2% -13.3% NPCE
Total Assets 110.21M 96.99M LUNG
Cash 52.69M 12.54M LUNG
Debt/Equity 1.11 4.97 LUNG
Current Ratio 4.05 4.94 NPCE
Free Cash Flow -18.51M -10.04M NPCE

Relative Price Performance (Last 90 Days)

NPCE 1M: -1.7% · 3M: -14.1% LUNG 1M: +65.3% · 3M: +34.7%

Current Technical Phase

NPCE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 45

RSI (14): 44.8 · Price: $12.46

LUNG

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.5% over 20 days), RSI 65

RSI (14): 64.6 · Price: $2.91

Fundamentals Snapshot

Metric NPCE LUNG
Market Cap — —
Forward P/E -57.6 -3.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.8% 0.8%
Operating Margin -0.2% -0.3%
EPS -0.57 -1.01
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, NPCE is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.